Catalyst Event
Biogen Inc (BIIB) · Other
From Akros U.S. Tech 100 Index (AUT100)
5/24/2026, 12:00:00 AM
FDA PDUFA action date for the supplemental Biologics License Application (sBLA) for a subcutaneous formulation of LEQEMBI is May 24, 2026; Medium importance is estimated due to uncertain market reaction scheduled.
Korean Translation
2026년 5월 24일 레켐비(LEQEMBI) 피하주사 제형의 보충적 생물의약품 허가신청(sBLA)에 대한 FDA PDUFA 목표일이 예정됨. 시장 반응 불확실로 중요도는 추정치이며 예정됨.
Related Recent Events
Hewlett Packard Enterprise Co (HPE) · Other
HPE Discover Las Vegas 2026, the company's flagship annual event, is scheduled to begin, running from June 15-18. Major announcements on AI, cloud, and networking are anticipated to drive market interest scheduled.
6/15/2026, 12:00:00 AM
Hewlett Packard Enterprise Co (HPE) · Earnings Release
Fiscal Q2 2026 earnings release is expected. The company guided for revenue between $9.6 billion and $10.0 billion and non-GAAP EPS between $0.51 and $0.55. High volatility is anticipated based on historical earnings reactions expected.
6/2/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 2027 earnings release is scheduled for May 20, 2026; Medium importance is assigned as earnings typically drive 5-10% volatility, and analysts forecast an EPS of $1.74-$1.76 estimated.
5/20/2026, 12:00:00 AM
Amgen Inc (AMGN) · Other
A quarterly dividend of $2.52 per share for Q2 2026 is scheduled, with an ex-dividend date of May 15, 2026; a price impact of ≥1% is estimated due to the routine nature of the distribution, scheduled.
5/15/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Q1 2026 earnings release is scheduled. High importance estimated due to expected market volatility.
5/13/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Analysts forecast EPS of approximately $0.62 forecasted. Q1 2026 earnings release scheduled. Low impact expected for routine announcement.
5/6/2026, 12:00:00 AM